Efficacy and Safety Information. Endo shall furnish Vernalis with efficacy and safety information reasonably requested by Vernalis to assist Vernalis in promoting the Product to Target Healthcare Professionals in the USA, including without limitation relevant clinical and safety data included in the NDA for the Product and additional information, if any, related to the efficacy and safety profile of the Product since the transfer of the NDA to Endo from Vernalis. Except for that information that is to be disclosed to Target Healthcare Professionals in connection with conducting Product Details, such information shall be treated as Confidential Information of Endo pursuant to
Efficacy and Safety Information. Each party shall furnish the other with efficacy and safety information in its possession as reasonably requested to assist each party in the performance of its obligations under this Agreement, including without limitation relevant clinical and safety data included in the NDA (or comparable filing in the Territory) for the Products and additional information, if any, related to the efficacy and safety profile of the Products. Except for that information that is to be disclosed to OB/GYN's in connection with conducting details, such information shall be treated as Confidential and Proprietary Information pursuant to Section 8 of this Agreement and shall not be disclosed to third parties without the prior written approval or direction of the party owning such Confidential and Proprietary Information.
Efficacy and Safety Information. Nastech shall furnish LICENSEE with such efficacy and safety information as is required by law and otherwise is in the possession or control of Nastech to assist LICENSEE in the marketing, promotion, sale and distribution of the Product.
Efficacy and Safety Information. Ligand shall furnish Co-Promotion Partner with efficacy and safety information reasonably requested by Co-Promotion Partner to assist Co-Promotion Partner in promoting the Product to Target Healthcare Professionals in the Territory, including without limitation relevant clinical and safety data included in the NDA for the Product and additional information, if any, related to the efficacy and safety profile of the Product since the Product's approval by the FDA. Except for that information that is to be disclosed to Target Healthcare Professionals in connection with providing Product Calls, such information shall be treated as Confidential Information of Ligand pursuant to Section 11 of this Agreement and shall not be disclosed to third parties without Ligand's prior written approval or direction.
Efficacy and Safety Information. During the Copromotion Period King shall furnish Wyeth with efficacy and safety information reasonably requested by Wyeth to assist Wyeth in promoting the Product(s) to Physicians in the Territory, including without limitation relevant clinical and safety data included in the NDA for the Product(s) and additional information, if any, related to the efficacy and safety profile of the Product(s) since the Product’s approval by the FDA. Except for that information that is to be disclosed to Physicians in connection with conducting Details, such information shall be treated as confidential and proprietary information pursuant to Section 12 of this Agreement and shall not be disclosed to third parties without King’s prior written approval or direction.
Efficacy and Safety Information. Bayer shall furnish Onyx with efficacy and safety information reasonably requested by Onyx to assist Onyx in promoting the Co-Promotion Collaboration Product to Target Healthcare Professionals in the United States, including without limitation relevant clinical and safety data included in the NDA for the Co- [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Promotion Collaboration Product and additional information, if any, related to the efficacy and safety profile of the Co-Promotion Collaboration Product.
Efficacy and Safety Information. KING shall furnish AHPC with efficacy and safety information reasonably requested by AHPC to assist AHPC in promoting the Product to Physicians in the Territory, including without limitation relevant clinical and safety data included in the NDA for the Product and additional information, if any, related to the efficacy and safety profile of the Product since the Product's approval by the FDA. Except for that information that is to be disclosed to Physicians in connection with conducting Details, such information shall be treated as confidential and proprietary information pursuant to Section 12 of this Agreement and shall not be disclosed to third parties without KING's prior written approval or direction.
Efficacy and Safety Information. King will furnish Inyx with efficacy and safety information reasonably requested by Inyx to assist Inyx in promoting the Products to Physicians in the Territory, including relevant clinical and safety data included in the NDA for the Products and additional information, if any, related to the efficacy and safety profile of the Products since the Products’ approval by the applicable Regulatory Authority. King will also provide Inyx with updates to annual reports required to be delivered by King pursuant to this Agreement. Except for that information that is to be disclosed to Physicians in connection with conducting Details, such information will be treated as the Confidential Information of King.
Efficacy and Safety Information. Santarus shall furnish Co-Promotion Partner with efficacy and safety information reasonably requested by Co-Promotion Partner to assist Co-Promotion Partner in promoting the Products to Co-Promotion Partner Target Healthcare Professionals in the Territory, including without limitation relevant clinical and safety data included in the NDA for each Product and additional information, if any, related to the efficacy and safety profile of the Products since each Product's respective approval by the FDA. Except for that information that is to be disclosed to Co-Promotion Partner Target Healthcare Professionals in connection with providing Product Calls, such information shall be treated as Confidential Information of Santarus pursuant to Section 11 of this Agreement and shall not be disclosed to third parties without Santarus' prior written approval or direction.
Efficacy and Safety Information. Galderma shall furnish PhotoMedex with efficacy and safety information reasonably requested by PhotoMedex to assist PhotoMedex in promoting the Product, including without limitation relevant clinical and safety data included in the NDA for the Product and additional information, if any, related to the efficacy and safety profile of the Product since the Product’s approval by the FDA.
